Canfite earnings
WebWho invested in CanFite BioPharma? CanFite BioPharma has 5 investors including Cybele Holdings and Cybele Holdings. How much funding has CanFite BioPharma raised to date? CanFite BioPharma has raised $80.4M. When was the last funding round for CanFite BioPharma? CanFite BioPharma closed its last funding round on Aug 12, … WebEarnings estimates and surprises for Can-Fite Biopharma Ltd ADR (CANF) are an important tool used to evaluate the company's overall strength and value of the stock. …
Canfite earnings
Did you know?
WebMar 30, 2024 · Can-Fite BioPharma Ltd. reported earnings results for the full year ended December 31, 2024. For the full year, the company reported sales was USD 0.81 million compared to USD 0.853 million a year ago. Net loss was USD 10.17 million compared to USD 12.62 million a year ago. WebJul 16, 2024 · Can-Fite BioPharma's mailing address is 10 BAREKET STREET KIRYAT MATALON P.O. BOX 7537, PETACH TIKVA L3, 4951778. The official website for the …
WebApr 6, 2024 · A high-level overview of Can-Fite BioPharma Ltd. (CANF) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and … WebMar 30, 2024 · Can-Fite Biopharma Ltd ADR (CANF) reported a 4th Quarter December 2024 loss of $1.11 per share on revenue of $0.2 million. The consensus estimate was a loss of $0.57 per share on revenue of $0.3 million. Revenue fell 3.4% compared to the same quarter a year ago.
WebJul 26, 2024 · Earnings Estimate Revisions for CanFite Biopharma Ltd This company is expected to earn -$0.35 per share for the fiscal year ending December 2024, which … WebThe Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
WebEdit. Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis.
WebJul 26, 2024 · CanFite Biopharma Ltd (CANF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). clicks beacon easter eggsWebMar 21, 2024 · All earnings call transcripts on Can-Fite BioPharma Ltd. (CANF) stock. Read or listen to the conference call. Download the investor presentation - earnings call slides. clicks beaufort westWebMar 30, 2024 · Can-Fite Biopharma Ltd ADR (CANF) reported a 4th Quarter December 2024 loss of $1.11 per share on revenue of $0.2 million. The consensus estimate was a … bnc video cable max lengthWeb2 days ago · Can-Fite BioPharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2.. CI. 03/17: Can-fite to conduct meetings at the bio-europe spring conference with pharma companies .. AQ. 03/13: Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compass.. CI. clicks beautyWebApr 10, 2024 · Can-Fite BioPharma Ltd. gab bekannt, dass das Unternehmen vom Ausschuss für Humanarzneimittel der Europäischen Arzneimittelagentur eine positive Stellungnahme zur Einreichung eines... 11 April 2024 clicks beard productsWebApr 10, 2024 · -- Can-Fite Biopharma Ltd teilte am Montag mit, dass es vom Ausschuss für Humanarzneimittel der Europäischen Arzneimittelagentur eine positive Stellungnahme zu seinem Zulassungsplan für eine... 11 April 2024 clicks beard growthWebJan 17, 2024 · Meanwhile, the Medical sector has returned an average of -12.7% on a year-to-date basis. This means that CanFite Biopharma Ltd is performing better than its sector in terms of year-to-date returns. Cellectar Biosciences, Inc. (CLRB) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the ... clicks beaufort west pharmacy